Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pomerantz

Showing results (211-220 of 254) with videos related to

Pageof 26
Sort By:
JCO Precision Oncology|September 14, 2022
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerJacob E Berchuck, Daniel Boiarsky, Rebecca Silver, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Analysis of evolutionary dynamics and clonal architecture in prostate cancerJake R Conway, Alok K Tewari, Sabrina Y Camp, et al.
Journal of the American Society of Nephrology : JASN|January 27, 2018
Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning ProtectionAlexander L Kolb, Peter R Corridon, Shijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate CancerKonrad H Stopsack, Joseph Vijai, Michael Conry, et al.
Cell|June 19, 2018
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate CancerDavid Y Takeda, Sándor Spisák, Ji-Heui Seo, et al.
Cancer|January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialRana R McKay, Wanling Xie, Xiaoyu Yang, et al.
Cancer Discovery|August 31, 2019
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 InactivationReyaz Ur Rasool, Ramakrishnan Natesan, Qu Deng, et al.
Plos Genetics|November 19, 2010
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesisMark M Pomerantz, Yashaswi Shrestha, Richard J Flavin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2019
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Ying Z Mazzu, Joshua Armenia, Goutam Chakraborty, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Pageof 26

Showing results (211-220 of 254) with videos related to

Sort By:
Pageof 26
JCO Precision Oncology|September 14, 2022
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerJacob E Berchuck, Daniel Boiarsky, Rebecca Silver, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2023
Analysis of evolutionary dynamics and clonal architecture in prostate cancerJake R Conway, Alok K Tewari, Sabrina Y Camp, et al.
Journal of the American Society of Nephrology : JASN|January 27, 2018
Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning ProtectionAlexander L Kolb, Peter R Corridon, Shijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate CancerKonrad H Stopsack, Joseph Vijai, Michael Conry, et al.
Cell|June 19, 2018
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate CancerDavid Y Takeda, Sándor Spisák, Ji-Heui Seo, et al.
Cancer|January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trialRana R McKay, Wanling Xie, Xiaoyu Yang, et al.
Cancer Discovery|August 31, 2019
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 InactivationReyaz Ur Rasool, Ramakrishnan Natesan, Qu Deng, et al.
Plos Genetics|November 19, 2010
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesisMark M Pomerantz, Yashaswi Shrestha, Richard J Flavin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2019
A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)Ying Z Mazzu, Joshua Armenia, Goutam Chakraborty, et al.
Nature Genetics|September 7, 2022
Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulationSylvan C Baca, Cassandra Singler, Soumya Zacharia, et al.
Pageof 26